The verdict
Tesamorelin suits a man who is not especially heavy but carries a stubborn, firm belly: normal or modestly raised weight, a large waist, and visceral fat that diet and training have not touched. GLP-1 medicines suit a man with obesity or overweight plus a related condition, especially prediabetes or diabetes, for whom losing a substantial amount of total weight is the main goal and visceral fat is part of the package.
The two are not interchangeable. One reshapes where fat sits; the other reduces how much there is overall.
Side-by-side comparison
| Tesamorelin | GLP-1 medicines (semaglutide, tirzepatide) | |
|---|---|---|
| FDA approval | Excess abdominal fat in adults with HIV lipodystrophy; other use is off-label | Chronic weight management and, for some brands, type 2 diabetes |
| Main target | Visceral fat | Total body weight, including visceral fat |
| Effect on body weight | Small; the label says it is not for weight loss | Large; about 15% on average with semaglutide 2.4 mg |
| Effect on muscle | No calorie deficit built in; lean mass held steady in extension studies | Some lean mass lost along with fat |
| Effect on blood sugar | Can raise glucose in some people; checked before starting | Lowers blood sugar |
| How it is taken | Daily injection | Weekly injection, or a daily semaglutide tablet |
| Key labs | IGF-1, glucose, A1C | Glucose, A1C, kidney function, lipids |
How each one works
Tesamorelin is a growth hormone releasing hormone analog. It prompts the pituitary to release more of your own growth hormone, which raises IGF-1 and shifts the body toward breaking down visceral fat. It does not suppress appetite, which is why weight changes little while the fat distribution changes.
GLP-1 medicines mimic gut hormones that signal fullness and slow stomach emptying, so you eat less. Fat comes off throughout the body, and visceral fat, which responds readily to an energy deficit, tends to fall faster than total weight. Tirzepatide adds a second hormone signal. Both lower blood sugar, which is why they began as diabetes medicines.
Visceral fat results compared
Tesamorelin’s trials measured visceral fat directly by CT. In a 26-week trial of 412 people with HIV, visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo. Closer to the men who ask about it today, a 12-month trial in 60 adults with abdominal obesity and reduced growth hormone secretion found visceral fat fell by 16 square centimeters on tesamorelin while it rose by 19 on placebo. Fat under the skin did not change significantly, and triglycerides and C-reactive protein improved. The gains depend on staying on treatment: in the extension phase described on the label, visceral fat climbed back by 16% to 22% within six months in people switched from tesamorelin to placebo.
GLP-1 results come from body scans in much larger weight-loss trials. In STEP 1, semaglutide 2.4 mg produced a 14.9% average loss of body weight over 68 weeks. A DXA substudy reported a 27.4% drop in visceral fat and a 19.3% drop in total fat, according to Endocrine Society coverage. The studies used different methods and different people, so these figures cannot be compared head to head, but the pattern is consistent: GLP-1 medicines produce bigger total changes, tesamorelin a more targeted one.
Muscle and glucose effects
Muscle is where GLP-1 plans need watching. In the same STEP 1 substudy, lean mass fell 9.7% alongside the fat loss. Protein intake, resistance training and the pace of loss all influence how much muscle is kept, and our answer on muscle loss on semaglutide covers what helps. Tesamorelin works differently: it does not create a calorie deficit, and in the label’s extension studies, men and women who stayed on it kept lean body mass steady through the second six months, while those switched to placebo lost about 1.8 kg of lean mass in one study.
Glucose runs the other way. GLP-1 medicines lower blood sugar, which is part of why they suit men with prediabetes or diabetes. The Egrifta SV label asks for a glucose check before starting tesamorelin and periodic monitoring for impaired glucose tolerance or diabetes, although the 12-month non-HIV trial above saw no change in fasting glucose or A1C. A man with poorly controlled blood sugar is usually a better fit for a GLP-1 medicine.
Side effects, cost and who should avoid each
Tesamorelin’s label lists joint pain, injection-site reactions, swelling, limb pain and muscle aches as common, requires IGF-1 monitoring, and rules it out with active cancer or a disrupted pituitary axis. MedlinePlus lists nausea, vomiting, diarrhea and constipation among common semaglutide effects, with pancreatitis and gallbladder problems among the serious ones; GLP-1 medicines are not used with a personal or family history of medullary thyroid cancer.
Convenience and cost differ too. Tesamorelin is a daily injection, and its cost depends on whether a brand or compounded preparation is used. GLP-1 medicines are weekly and tend to continue long term for maintenance. Both require follow-up labs. If you are also weighing sermorelin, see tesamorelin vs sermorelin.
How Ultimate Male decides
At Ultimate Male, the choice follows the measurements. After a free 10-minute call, you get on-site labs including glucose markers and IGF-1, plus a body composition analysis and waist measurement at San Gabriel or Downey. Our page on visceral fat in men explains why that number gets attention, and the fastest ways men lose visceral fat covers the non-drug basics that come first.
A PA-C or MD then explains which path fits: the tesamorelin peptide program with IGF-1 follow-up, the medical weight loss program with semaglutide or tirzepatide, or neither for now. The IGF-1 blood test page explains the marker that guides tesamorelin dosing.
